 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.

Slides:



Advertisements
Similar presentations
DO YOU HAVE THE METABOLIC SYNDROME? You're never too young to have it Jacqueline A. Eberstein, R.N.
Advertisements

Definitions Body Mass Index (BMI) describes relative weight for height: weight (kg)/height (m 2 ) Overweight = 25–29.9 BMI Obesity = >30 BMI.
Obesity.
CONTROLLING YOUR RISK FACTORS Taking the Steps to a Healthy Heart.
U.S. Dept of Health and Human Services. National High Blood Pressure Education Program. Seventh Report of Joint National Committee on Prevention, Detection,
SUPERSIZED NATION By Jennifer Ericksen August 24, 2007.
Diabesity Management Colette Walter, NP. Objectives 1. Pharmacologic management and understanding of treatment related to the overweight diabetic patient.
Exercise the Medicine of Choice Reducing Cardiovascular Risk Dr. Lynn Panton Florida State University College of Human Sciences Department of Nutrition,
Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin (insulin is a hormone that regulates blood sugar) or.
What is Diabetes?.
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Therapy of Type 2 Diabetes Mellitus: UPDATE
METABOLIC Syndrome: a Global Perspective
Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.
Physical Wellness Health A / B. Disease Prevention Regular physical activity lowers your risk of many chronic and disabling disease. Why? What is a chronic.
The cilium 1 microscopic structure NSCT. The Cilium 2 intracellular trafficking NSCT.
Oral Hypoglycemic Drugs
Diabetes and You Vidya Sundaram, MD. Diabetes in Asian Indians The prevalence of diabetes in rural India is 2 percent The prevalence of diabetes in rural.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.
GLP-1 Effectiveness, Mechanisms of Action and Potential Part 1.
Journal Club 2009 年 1 月 29 日(木) 8 : 20 ~ 8 : 50 B 棟 8 階カンファレンスルーム 薬剤部 TTSP 石井 英俊.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.
After eating, most food is turned into glucose, the body’s main source of energy. What Happens When We Eat? American Diabetes Association.
Part 7. GLUT2 AMG Uptake NGTT2DMNGTT2DM AMG=methyl-  -D-[U 14 C]-glucopyranoside; CPM=counts per minute. Rahmoune H, et al. Diabetes. 2005;54:
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
EXPLAINS Hypoglycemia. EX PLAINS Exogenous Insulin Basal: Lantus Levemir NPH Bolus Novolg Humolog Apidra Regular Exubera(inhaled Insulin )
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 3 Stan Schwartz MD, FACP, FACE.
GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
SGLT-2 Inhibitor with Incretins.
JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA Tablets contain sitagliptin.
Part 2 of 2.  GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activa­tor inhibitor-1 (PAI-1), vascular.
A Diabetes Outcome Progression Trial
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 3 of 5.
Diabetes Prevention Program (DPP)
Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA.
Part 6.
Risk Factor Modification in CCR. How does CR work?
GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.
An American Epidemic. Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI ≥30 kg/m 2 ) Diabetes
Diabetes. Objectives: Diabetes Mellitus (DM) Discuss the prevalence of diabetes in the U.S. Contrast the main types of diabetes. Describe the classic.
Presented by Slyter Nutrition Consulting Services.
Glucose Metabolism Dr Lenon T Gwaunza MBChB, BSc (Hons), MSc (UCL)
Hippocrates Prize Prof A. Kokkinos (Greece).
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions?
6.Fat- increased lipolysis, inc FFA
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.
GLP-1 Agonists and Cardiovascular Health
Chapter 10 Diet and Health
Diet, Obesity, and Chronic Disease
GLP-1 Agonists and DPP-4 Inhibitors How do they work?
1.
Level of risk factor control in the overall sample and by gender
GLP-1 Agonists and DPP-4 Inhibitors How do they work?
GLP-1 Agonists and DPP-4 Inhibitors How do they work?
New frontiers in Diabetes management
Hormones that Affect Blood Sugar
Incretin Physiology in Type 2 Diabetes Mellitus
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.
Presentation transcript:

 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and cardiovascular outcomes

 Obesity is a common problem especially with Type-2 diabetics  Obesity leads to several physiologic effects including cardiovascular disease and increased mortality  Cardiovascular disease is responsible for 65% of deaths in people with type-2 diabetes Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Diabetes Public Health Resource. Statistics: Diabetes Surveillance, Accessed August, 2003 at:

Overweight Data are from 1 million men and women (average age, 57 years) followed for 16 years who never smoked and had no history of disease at enrollment. Calle EE, et al. N Engl J Med. 1999;341: Normal weightObese Relative Risk of Cardiovascular Disease Mortality > >40 BMI, kg/m 2 Women Men

Δ A1C (%) * Δ HDL Cholesterol (mg/dL) * Intensified Lifestyle Intervention, 8.6% Weight Loss Diabetes Support and Education, 0.7% Weight Loss Randomized, controlled trial; n = 5145; Patients with type 2 diabetes, age >18 y; Mean ± SE Intensified lifestyle intervention (n = 2496) vs diabetes support and education (n = 2463) therapy; *P<0.001 between groups Look AHEAD Research Group. Diabetes Care. 2007;30: Δ Triglycerides (mg/dL) * Δ Blood Pressure (mm Hg) * * SystolicDiastolic

Release of active incretins GLP-1 and GIP  Blood glucose in fasting and postprandial states Ingestion of food  Glucagon (GLP-1)  Hepatic glucose production GI tract DPP-4 enzyme Inactive GLP-1 X DPP-4 inhibitor  Incretin hormones GLP-1 and GIP are released by the intestine throughout the day, and their levels  in response to a meal.  Incretin Mimetics are resistant to DPP-4 inactivation  Insulin (GLP-1and GIP) Glucose- dependent Glucose dependent Pancreas Inactive GIP GLP-1=glucagon-like peptide-1; GIP=glucose-dependent insulinotropic polypeptide. Concentrations of the active intact hormones are increased by DPP-4 inhibition, thereby increasing and prolonging the actions of these hormones. Beta cells Alpha cells  Glucose uptake by peripheral tissue Incretin Mimetic